Summary & Overview
CPT 81290: Genetic Test for MCOLN1 (Mucolipin 1) Variants
CPT code 81290 denotes a laboratory molecular test to detect common variants in the MCOLN1 gene (mucolipin 1). As a targeted genetic diagnostic assay, this code is used when evaluating patients for conditions related to MCOLN1 mutations. Nationally, accurate coding for genetic tests affects claims processing, clinical decision support, and population-level surveillance of rare genetic disorders.
This analysis covers major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for 81290, typical sites of service, common billing considerations, and the payer landscape addressed in the publication. The report highlights benchmarking topics such as coverage patterns, utilization considerations, and coding alignment with laboratory workflows where available.
The publication is intended for health policy analysts, billing and coding professionals, laboratory directors, and payers. It provides an overview of clinical intent for 81290, guidance on what to expect in claims and coverage discussions, and directs readers to sections with payer-specific coverage trends, common modifiers used in practice, and gaps where additional documentation or policy clarification may be required. Data not available in the input will be noted in relevant sections.
Billing Code Overview
CPT code 81290 describes a laboratory test performed by a lab analyst to detect the presence of common changes in the gene for mucolipin 1 (MCOLN1). The service is a genetic test focused on identifying molecular variants associated with disorders linked to MCOLN1.
-
Service type: Genetic molecular diagnostic testing
-
Typical site of service: Clinical laboratory or reference molecular diagnostics laboratory
Clinical & Coding Specifications
Clinical Context
A pediatric or adult patient with progressive neurodevelopmental regression, hypotonia, vision impairment, recurrent respiratory infections, coarse facies, or organomegaly is referred for genetic testing to evaluate for mucolipin 1 (MCOLN1) gene variants consistent with mucolipidosis type IV. The typical workflow begins with a genetics or neurology consultation documenting clinical features and family history. A blood sample or buccal swab is collected in an appropriate container and sent to a molecular diagnostics laboratory. The lab analyst performs 81290 to detect common pathogenic and likely pathogenic sequence changes in the MCOLN1 gene using targeted mutation analysis or sequencing platforms. Results are interpreted by a molecular pathologist or clinical laboratory geneticist and reported to the ordering provider, who discusses implications for diagnosis, prognosis, carrier testing, and family counseling. Insurance billing uses the lab technical component; modifier use depends on payer rules and whether professional interpretation is billed separately.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician or laboratory professional interpretation separate from the technical testing. |